{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:13:07Z","timestamp":1789636387531,"version":"4.0.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jiph.2020.10.015","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T12:54:46Z","timestamp":1603716886000},"page":"1856-1861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach"],"prefix":"10.1016","volume":"13","author":[{"given":"Purushothaman","family":"Indu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-8104","authenticated-orcid":false,"given":"Marimuthu Ragavan","family":"Rameshkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasingam","family":"Arunagirinathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif Abdullah","family":"Al-Dhabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariadhas","family":"Valan Arasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savarimuthu","family":"Ignacimuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2020.10.015_bib0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jiph.2020.10.015_bib0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jiph.2020.10.015_bib0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jiph.2020.10.015_bib0020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/v9120364","article-title":"Identification of alpha and beta coronavirus in wildlife species in France: bats, rodents, rabbits, and hedgehogs","volume":"9","author":"Monchatre-Leroy","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.jiph.2020.10.015_bib0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2020.10.015_bib0030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jiph.2020.10.015_bib0035","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARSCoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jiph.2020.10.015_bib0040","series-title":"Coronavirus disease (COVID-19) situation report \u2014 118","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.jiph.2020.10.015_bib0045","first-page":"166","article-title":"In silico identification of potent FDA approved drugs against Coronavirus COVID-19 main protease: a drug repurposing approach","volume":"7","author":"Kumar","year":"2020","journal-title":"Chem Biol Lett"},{"key":"10.1016\/j.jiph.2020.10.015_bib0050","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2020.10.015_bib0055","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2020.10.015_bib0060","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/CM9.0000000000000744","article-title":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province","volume":"133","author":"Liu","year":"2020","journal-title":"Chin Med J"},{"key":"10.1016\/j.jiph.2020.10.015_bib0065","unstructured":"EU Clinical Trial Register. 2020. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=covid-19."},{"key":"10.1016\/j.jiph.2020.10.015_bib0070","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fgene.2019.00368","article-title":"Informatics and computational methods in natural product drug discovery: a review and perspectives","volume":"10","author":"Romano","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.jiph.2020.10.015_bib0075","first-page":"1","article-title":"Modeling antimalarial and antihuman African trypanosomiasis compounds: a ligand- and structure-based approaches","volume":"23","author":"Gahtori","year":"2019","journal-title":"Mol Divers"},{"key":"10.1016\/j.jiph.2020.10.015_bib0080","first-page":"1","article-title":"Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2\u2032-O-ribose methyltransferase","volume":"2","author":"Khan","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jiph.2020.10.015_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117627","article-title":"Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease","volume":"251","author":"Kandeel","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.jiph.2020.10.015_bib0090","first-page":"1","article-title":"Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock","volume":"2","author":"Mothay","year":"2020","journal-title":"Virus Disease"},{"key":"10.1016\/j.jiph.2020.10.015_bib0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/1573406414666181015152511","article-title":"Novel guanosine derivatives as anti-HCV NS5b polymerase: a QSAR and molecular docking study","volume":"15","author":"Elfiky","year":"2019","journal-title":"Med Chem"},{"key":"10.1016\/j.jiph.2020.10.015_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.jiph.2020.10.015_bib0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open babel: an open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J Cheminform"},{"key":"10.1016\/j.jiph.2020.10.015_bib0110","first-page":"14","article-title":"Using AutoDock for ligand-receptor docking","volume":"8","author":"Morris","year":"2008","journal-title":"Curr Protoc Bioinformatics"},{"key":"10.1016\/j.jiph.2020.10.015_bib0115","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btaa645","article-title":"COVID-19 Docking Server: A meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19","author":"Kong","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jiph.2020.10.015_bib0120","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2020.10.015_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2019.113806","article-title":"Analysis of preferred codon usage in the coronavirus N genes and their implications for genome evolution and vaccine design","volume":"277","author":"Sheikh","year":"2020","journal-title":"J Virol Methods"},{"key":"10.1016\/j.jiph.2020.10.015_bib0130","series-title":"Potential inhibitor of COVID19 main protease (Mpro) from several medicinal plant compounds by molecular docking study","first-page":"1","author":"Khaerunnisa","year":"2020"},{"key":"10.1016\/j.jiph.2020.10.015_bib0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","article-title":"Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond","volume":"155","author":"Chaudhuri","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.jiph.2020.10.015_bib0140","first-page":"166","article-title":"In silico identification of potent COVID-19 main protease inhibitors from FDA approved antiviral compounds and active phytochemicals through molecular docking: a drug repurposing approach","volume":"7","author":"Chandel","year":"2020","journal-title":"Chem Biol Lett"},{"key":"10.1016\/j.jiph.2020.10.015_bib0145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jpha.2020.03.009","article-title":"Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants","volume":"10","author":"Qamar","year":"2020","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.jiph.2020.10.015_bib0150","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2020.10.015_bib0155","first-page":"1","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"4","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.jiph.2020.10.015_bib0160","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical \ufb01ndings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.jiph.2020.10.015_bib0165","article-title":"Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking","author":"Chang","year":"2020","journal-title":"Preprints"},{"key":"10.1016\/j.jiph.2020.10.015_bib0170","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/v12040445","article-title":"Molecular investigation of SARS\u2013CoV-2 proteins and their interactions with antiviral drugs","volume":"12","author":"Calligari","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jiph.2020.10.015_bib0175","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown ap-parent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.jiph.2020.10.015_bib0180","first-page":"1","article-title":"SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective","volume":"26","author":"Elfiky","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jiph.2020.10.015_bib0185","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.jiph.2020.10.015_bib0190","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nature Biotechnol"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034120307127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034120307127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:09:13Z","timestamp":1761750553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034120307127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1876034120307127"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2020.10.015","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2020.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}